Study guide
17.6 Mental Health Screening & Substance Use Disorders
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
17.6 Mental Health Screening & Substance Use Disorders
Key Takeaways Explain This Topic AI
A PHQ-2 score of 3 or higher is positive and mandates the full PHQ-9, on which 20 or higher indicates severe depression requiring combination treatment and psychiatric involvement.
In women an AUDIT-C score of 3 or higher indicates hazardous drinking, and NIAAA low-risk limits are no more than 3 drinks in a day and 7 per week.
Buprenorphine and methadone are first-line for opioid use disorder and reduce mortality, and buprenorphine no longer requires a special waiver to prescribe.
Naloxone should be co-prescribed to anyone at risk of overdose, including patients on higher-dose opioid therapy and their household members.
Varenicline and combination nicotine replacement are the most effective tobacco cessation pharmacotherapies within the 5 A's framework.
Last updated: September 2026
- Mental Health & Behavioral Health Screening
- Major Depressive Disorder (MDD): PHQ-2 & PHQ-9 Algorithm
The USPSTF recommends universal depression screening in all adults in primary care.
Initial Screen (PHQ-2): Consists of two questions assessing frequency of depressed mood and anhedonia over the past 2 weeks (scored 0 to 6). A score ≥3 is considered positive and mandates immediate administration of the full PHQ-9 .
PHQ-9 Severity Scoring (0 to 27):
5 to 9: Mild depression (supportive counseling, lifestyle modification, re-evaluate in 4–8 weeks).
10 to 14: Moderate depression (consider psychotherapy and/or first-line pharmacotherapy).
15 to 19: Moderately severe depression (initiate pharmacotherapy and/or psychotherapy).
≥ 20: Severe depression (immediate combination pharmacotherapy and psychiatric consultation).
PHQ-9 Question 9 Suicide Risk Protocol: Question 9 asks about "thoughts that you would be better off dead, or of hurting yourself in some way." Any non-zero response (1, 2, or 3) mandates an immediate, comprehensive clinical suicide risk assessment before the patient leaves the clinical setting :
Assess suicidal ideation, intent, specific plans, lethal means access (especially firearms and medications), previous suicide attempts, and active protective factors.
Complete a collaborative Stanley-Brown Safety Plan: identify personal warning signs, internal coping strategies, social distractions, emergency contacts, and the 988 Suicide & Crisis Lifeline.
If active suicidal intent with high lethality or inability to maintain safety is present, initiate emergency psychiatric evaluation (voluntary or involuntary evaluation per state statute).
Generalized Anxiety Disorder (GAD-7)
Screening using the validated GAD-7 tool evaluates excessive worry, restlessness, irritability, and muscle tension over the prior 2 weeks:
Scores 5 to 9: Mild anxiety.
Scores 10 to 14: Moderate anxiety (threshold indicating likely GAD; initiate treatment).
Scores ≥ 15: Severe anxiety.
Evidence-Based Psychotherapy & Pharmacotherapy
Psychotherapy: Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Mindfulness-Based Stress Reduction (MBSR) are highly effective first-line non-pharmacologic modalities.
First-Line Pharmacotherapy for Depression and Anxiety:
Selective Serotonin Reuptake Inhibitors (SSRIs): Escitalopram (10–20 mg daily), Sertraline (50–200 mg daily), Fluoxetine (20–60 mg daily).
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine XR (75–225 mg daily), Duloxetine (30–60 mg daily).
Critical Patient Education Points:
Therapeutic Latency: Educate the patient that antidepressant and anxiolytic clinical effects require 2 to 4 weeks to emerge, with maximal therapeutic efficacy reached at 6 to 8 weeks.
Transient Initial Side Effects: Inform patient that mild nausea, headache, jitteriness, and insomnia commonly occur in the first 7 to 14 days and typically self-resolve.
Black Box Warning: FDA warning regarding a potential transient increase in suicidal thoughts and behaviors in children, adolescents, and young adults up to age 24 during initial dose titration; schedule close follow-up within 1 to 2 weeks of initiation.
Discontinuation Syndrome: Instruct patient to never abruptly stop taking SSRIs or SNRIs. Abrupt cessation can precipitate Antidepressant Discontinuation Syndrome (flu-like symptoms, nausea, insomnia, dizziness, sensory "brain zaps", and severe rebound anxiety); taper gradually over weeks to months.
- Substance Use Disorders: SBIRT, Alcohol, Tobacco & Opioids
- The SBIRT Framework
Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based public health approach integrated into primary care to identify, reduce, and prevent problematic substance use.
Alcohol Screening & Risky Drinking Thresholds
AUDIT-C (Alcohol Use Disorders Identification Test-Concise): A 3-item validated screening questionnaire scored 0 to 12. In women, an AUDIT-C score ≥3 indicates hazardous / risky drinking or an active alcohol use disorder.
NIAAA Drinking Thresholds for Non-Pregnant Women: Low-risk drinking is defined as no more than 3 standard drinks on any single day AND no more than 7 standard drinks per week . (One standard drink = 12 oz beer [5%], 5 oz wine [12%], or 1.5 oz distilled spirits [40%]). For pregnant individuals or individuals attempting conception, zero alcohol consumption is safe.
Tobacco Cessation: The "5 A's" Model & Pharmacotherapy
Ask: Identify and document tobacco use status at every clinical visit.
Advise: Strongly urge all tobacco users to quit in a clear, non-judgmental, personalized manner.
Assess: Determine willingness to make a quit attempt within the next 30 days.
Assist: Aid the patient with a quit plan, behavioral counseling, and pharmacotherapy.
Arrange: Schedule follow-up contact within 1 week of the designated quit date.
First-Line Cessation Pharmacotherapy:
Nicotine Replacement Therapy (NRT): Combination therapy (long-acting transdermal nicotine patch combined with short-acting nicotine gum or lozenge for breakthrough cravings) achieves superior cessation rates compared to monotherapy.
Bupropion SR: Norepinephrine-dopamine reuptake inhibitor (150 mg daily x 3 days, then 150 mg BID). Contraindicated in patients with active or past seizure disorders or eating disorders (anorexia, bulimia).
Varenicline (Chantix): Alpha-4 beta-2 nicotinic receptor partial agonist (titrated to 1 mg PO BID). Demonstrates the highest single-agent smoking cessation efficacy.
Opioid Use Disorder (OUD) & Harm Reduction
Harm Reduction Principles: Universal, non-stigmatizing, non-punitive care. Provide access to sterile injection supplies, fentanyl test strips, and hepatitis C / HIV screening.
Universal Naloxone (Narcan) Co-Prescribing: Prescribe intranasal naloxone (4 mg nasal spray) to all individuals taking opioid analgesics who have risk factors for overdose (high daily dose ≥50 morphine milligram equivalents [MME], concurrent benzodiazepine or alcohol use, personal history of overdose, or substance use disorder) and to any individual with suspected illicit opioid exposure.
Medication for Opioid Use Disorder (MOUD):
Buprenorphine: Partial mu-opioid receptor agonist with high receptor affinity and a clinical ceiling effect on respiratory depression (commonly co-formulated with naloxone as Suboxone). Prescribed autonomously by CNMs in outpatient office settings under federal guidelines eliminating the former DATA 2000 X-waiver requirement.
Methadone: Full mu-opioid receptor agonist; highly effective in pregnancy to prevent opioid withdrawal and improve perinatal outcomes; dispensed through federally licensed Opioid Treatment Programs (OTPs).
Naltrexone: Full opioid antagonist; requires a strict 7- to 14-day opioid-free washout period prior to administration to avoid precipitating severe acute withdrawal; less favorable in pregnancy.